Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo

International Journal of Pharmaceutics

Volumn 363, Issue 1-2, 2008, Pages 155-161

  Song, Shuxian ^a   Liu, Dan ^a   Peng, Jinliang ^a   Sun, Ye ^a   Li, Zonghai ^b   Gu, Jian Ren ^b   Xu, Yuhong ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

EGFR; Liposome; Peptide ligand; Tumor targeting

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; LIPOSOME; PEPTIDE; PEPTIDE GE 11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DEVICE; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXTRAVASATION; DRUG TARGETING; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; ENDOCYTOSIS; FEASIBILITY STUDIES; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; LIGANDS; LIPIDS; LIPOSOMES; LUNG NEOPLASMS; MICE; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51649093438     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.07.012     Document Type: Article

References (43)

1. Ahmad I., Longenecker M., Samuel J., and Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53 (1993) 1484-1488
2. Allen T.M., Hansen C., Martin F., Redemann C., and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066 (1991) 29-36
3. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., Taki T., Shuto S., Matsuda A., and Oku N. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 520 (2002) 167-170
4. Bangham A.D., Standish M.M., and Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13 (1965) 238-252 No abstract available
5. Bangham A.D. Membrane models with phospholipids. Prog. Biophys. Mol. Biol. 18 (1968) 29-95
6. Bohl Kullberg E., Bergstrand N., Carlsson J., Edwards K., Johnsson M., Sjoberg S., and Gedda L. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug. Chem. 13 (2002) 737-743
7. Cheng Z., Levi J., Xiong Z., et al. Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug. Chem. 17 (2006) 662-669
8. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., and Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9 (2003) 6551-6559
9. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., and Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239 (1995) 133-144
10. Haran G., Cohen R., Bar L.K., and Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151 (1993) 201-215 (Erratum in: Biochim. Biophys. Acta (1190) 1994, 197)
11. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4607-4612
12. Iden D.L., and Allen T.M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta 1513 (2001) 207-216
13. Ishida T., Iden D.L., and Allen T.M. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 460 (1999) 129-133
14. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006) 6732-6740
15. Kok R.J., Schraa A.J., Bos E.J., Moorlag H.E., Asgeirsdottir S.A., Everts M., Meijer D.K., and Molema G. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug. Chem. 13 (2002) 128-135
16. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., and Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070 (1991) 187-192
17. Li Z., Zhao R., Wu X., Sun Y., Yao M., Li J., Xu Y., and Gu J. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19 (2005) 1978-1985
18. Lopes de Menezes D.E., Pilarski L.M., and Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58 (1998) 3320-3330
19. Lutsenko S.V., Feldman N.B., and Severin S.E. Cytotoxic and antitumor activities of doxorubicin conjugates with the epidermal growth factor and its receptor-binding fragment. J. Drug Target. 10 (2002) 567-571
20. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., and Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 100 (2004) 41-52
21. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., and Park J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63 (2003) 3154-3161
22. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., Kirpotin D.B., and Park J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65 (2005) 11631-11638
23. Mamot C., Ritschard R., Kung W., Park J.W., Herrmann R., and Rochlitz C.F. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Target. 14 (2006) 215-223
24. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., and Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1234 (1995) 74-80
25. Mayer L.D., Tai L.C., Bally M.B., Mitilenes G.N., Ginsberg R.S., and Cullis P.R. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta 1025 (1990) 143-151
26. Mayhew E.G., Lasic D., Babbar S., and Martin F.J. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int. J. Cancer 51 (1992) 302-309
27. Moreira J.N., Ishida T., Gaspar R., and Allen T.M. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res. 19 (2002) 265-269
28. Morpurgo M., Kirschner M., and Radu A. An approach to increased polyplex gene delivery by peptides selected from a phage display library. J. Biochem. Biophys. Methods 1 (2002) 31-43
29. Oba M., Fukushima S., Kanayama N., Aoyagi K., Nishiyama N., Koyama H., and Kataoka K. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alpha(v)beta(3) and alpha(v)beta(5) integrins. Bioconjug. Chem. (2007) (Epub ahead of print)
30. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., and Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66 (2006) 10073-10082
31. Roberts M.J., Bentley M.D., and Harris J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54 (2002) 459-476
32. Saul J.M., Annapragada A.V., and Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 114 (2006) 277-287 (Epub 2006)
33. Schiffelers R.M., Koning G.A., ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., Kok R.J., Molema G., and Storm G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91 (2003) 115-122
34. Ntziachristos V., Bremer C., and Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13 (2003) 195-208
35. Schmidt M., Vakalopoulou E., Schneider D.W., and Wels W. Construction and functional characterization of scFv(14E1)-ETA: a novel, highly potent antibody-toxin specific for the EGF receptor. Br. J. Cancer 75 (1997) 1575-1584
36. Takikawa M., Kikkawa H., Asai T., Yamaguchi N., Ishikawa D., Tanaka M., Ogino K., Taki T., and Oku N. Suppression of GD1alpha ganglioside-mediated tumor metastasis by liposomalized WHW-peptide. FEBS Lett. 466 (2000) 381-384
37. Tanaka T., Shiramoto S., Miyashita M., Fujishima Y., and Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277 (2004) 39-61
38. Vaage J., Mayhew E., Lasic D., and Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 51 (1992) 942-948
39. Woodle M.C., and Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1113 (1992) 171-199
40. Woodle M.C., Scaria P., Ganesh S., Subramanian K., Titmas R., Cheng C., Yang J., Pan Y., Weng K., Gu C., and Torkelson S. Sterically stabilized polyplex: ligand-mediated activity. J. Control. Release 74 (2001) 309-311
41. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., and Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53 (1993) 3765-3770
42. Wu X., Zhao R., Li Z., et al. A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2. Biochem. Biophys. Res. Commun. 315 (2004) 1004-1010
43. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756